With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.5317-33-9,3-(4-Methylpiperazin-1-yl)propan-1-ol,as a common compound, the synthetic route is as follows.
Alternative preparation of 3-(4-methylpiperazin-1-yl)propyl{3-[3-(3,5-difluorophenyl)-6-oxo-6H-pyridazin-1-ylmethyl]phenyl}carbamate 600 mg (2.02 mmol) of bis(trichloromethyl) carbonate and 2.10 ml (15.1 mmol) of triethylamine is added successively to a solution, kept at 0 C., of 1.55 g (4.95 mmol) of 2-(3-aminobenzyl)-6-(3,5-difluorophenyl)-2H-pyridazin-3-one in 20 ml of dichloromethane. 850 mg (5.37 mmol) of 3-(N-methylpiperazine)propan-1-ol is then added, and the reaction mixture is stirred at room temperature for 18 hours. The reaction mixture is partitioned between 1 N NaOH and dichloromethane. The organic phase is dried over sodium sulfate and evaporated. The residue is chromatographed on a silica-gel column with dichloromethane/methanol: 3-(4-methylpiperazin-1-yl)propyl{3-[3-(3,5-difluorophenyl)-6-oxo-6H-pyridazin-1-ylmethyl]phenyl}carbamate as colourless crystals., 5317-33-9
The synthetic route of 5317-33-9 has been constantly updated, and we look forward to future research findings.
Reference：
Patent; MERCK PATENT GESELLSCHAFT MIT BESCHRAeNKTER HAFTUNG; US2011/136819; (2011); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics